Strategies for more effective and reliable ADME. 30-31 March 2004, London, UK.

This conference was organised by Vision in Business, in order to address the issue that 'more than 40% of drug preclinical failure is due to ADME-related issues and many drugs are later withdrawn because of unanticipated drug-drug interactions (C Masimirembwa, AstraZeneca Mölndal, Sweden). Academic and industrial scientists were brought together to discuss and present current knowledge/theories on subjects of importance in preclinical and clinical drug development. These included in vivo/in vitro correlations, approaches and experimental models used, in silico models and methods, metabolic databases and their application, as well as safety and financial outcomes. Participants were challenged by the issues covered and encouraged to share their own experiences and opinions during extensive discussions with other scientists.